Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Cash from Operations (2016 - 2025)

Fortress Biotech has reported Cash from Operations over the past 13 years, most recently at 12544000.0 for Q4 2025.

  • Quarterly results put Cash from Operations at 12544000.0 for Q4 2025, up 2.81% from a year ago — trailing twelve months through Dec 2025 was 65777000.0 (up 17.97% YoY), and the annual figure for FY2025 was 65777000.0, up 17.97%.
  • Cash from Operations for Q4 2025 was 12544000.0 at Fortress Biotech, down from 6110000.0 in the prior quarter.
  • Over the last five years, Cash from Operations for FBIO hit a ceiling of 6110000.0 in Q3 2025 and a floor of 47844000.0 in Q4 2022.
  • Median Cash from Operations over the past 5 years was 26473500.0 (2024), compared with a mean of 28506700.0.
  • Biggest five-year swings in Cash from Operations: crashed 116.06% in 2022 and later soared 69.54% in 2025.
  • Fortress Biotech's Cash from Operations stood at 38696000.0 in 2021, then fell by 23.64% to 47844000.0 in 2022, then rose by 26.98% to 34935000.0 in 2023, then skyrocketed by 63.05% to 12907000.0 in 2024, then grew by 2.81% to 12544000.0 in 2025.
  • The last three reported values for Cash from Operations were 12544000.0 (Q4 2025), 6110000.0 (Q3 2025), and 27560000.0 (Q2 2025) per Business Quant data.